After signing up, you'll start to receive regular news updates from us.
Xenogen Announces Target Validation Collaboration Agreement with Schering-Plough
Complete the form below to unlock access to ALL audio articles.
Xenogen Biosciences, acquired on August 9, 2006, by Caliper Life Sciences, Inc. has announced a target validation collaboration with Schering-Plough Corporation, under which Xenogen Biosciences will utilize its proprietary Serial Phenotyping Compression Technology (SPCT) to characterize high value targets resulting from drug discovery research conducted by the Schering-Plough Research Institute.
SPCT evaluates the physiological and behavioral impact of such high value targets by utilizing a battery of 85 pharmacologically-validated challenge or bioassays (measuring over 400 individual parameters), and covering most therapeutic areas.
The recently signed phenotypic characterization agreement expands on a previous gene targeting agreement aimed at the creation of standard and conditional gene knockouts, both of which contribute to a fuller understanding of the biological effects associated with the deletion of a gene's function.
